Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624013 · ClinicalTrials.gov registry record · Phase 4
Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00624013 is a Phase 4 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 89 participants.
The verdict
NCT00624013, a Phase 4 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This proposed study will test the following hypothesis: Treating depression in Hispanics and African Americans with diabetes will improve their HbA1c and quality of life while on intervention and six months after intervention.
Interventions
- DRUG Placebo
- DRUG sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624013
The ClinicalTrials.gov registry entry for NCT00624013 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00624013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624013 about?
NCT00624013 is a clinical study titled "Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.". This proposed study will test the following hypothesis: Treating depression in Hispanics and African Americans with diabetes will improve their HbA1c and quality of life while on intervention and six months after intervention.
What is the current status of trial NCT00624013?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2006-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00624013?
The interventions under investigation include: Placebo (DRUG), sertraline (DRUG).
Who is sponsoring clinical trial NCT00624013?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.